Cortical Atrophy Predicts Progression to Dementia in Early-Onset Alzheimer’s
- Baseline cortical atrophy measured within a specific brain signature can predict how quickly patients with early-onset Alzheimer disease will progress from mild cognitive impairment to dementia, according to...
- Researchers at Massachusetts General Hospital and Harvard Medical School in Boston examined 130 patients aged 40 to 64 years.
- Faster progression to dementia was predicted by greater baseline atrophy within the early-onset Alzheimer disease signature, yielding a hazard ratio of 1.24 per one-standard deviation increase in atrophy.
Baseline cortical atrophy measured within a specific brain signature can predict how quickly patients with early-onset Alzheimer disease will progress from mild cognitive impairment to dementia, according to a study published August 26 in Neurology.
Brain Scan Biomarker Forecasts Early-Onset Alzheimer’s Decline
Researchers at Massachusetts General Hospital and Harvard Medical School in Boston examined 130 patients aged 40 to 64 years. These participants had biomarker-supported sporadic early-onset Alzheimer disease at the mild cognitive impairment stage, alongside 97 cognitively normal controls. Led by Thiago Paranhos, M.D., the research team focused on the early-onset Alzheimer disease signature. This specific set of predominantly parietotemporal regions shows greater atrophy in these patients than in controls.
Hazard Ratios and Statistical Fit
Faster progression to dementia was predicted by greater baseline atrophy within the early-onset Alzheimer disease signature, yielding a hazard ratio of 1.24 per one-standard deviation increase in atrophy. Investigators also used the global Clinical Dementia Rating to measure clinical severity across participants.
When researchers added the early-onset Alzheimer disease signature atrophy burden to a model that already included baseline clinical severity, model fit improved significantly. This was demonstrated by a decrease in the Akaike Information Criterion of -4.5.
The Search for Better Prognostic Tools
This brain scan biomarker we developed may help predict how quickly the disease will progress in each individual, giving physicians, people with early-onset Alzheimer’s disease and their families better information about what to expect and allowing earlier clinical trial enrollment for treatments that may improve outcomes.
Psychiatry Advisor
Managing Younger Patient Populations
The identification of this structural magnetic resonance imaging biomarker addresses a critical gap in managing younger populations affected by the condition. By quantifying cortical atrophy within vulnerable parietotemporal regions, clinicians gain a more precise method for evaluating individual risk trajectories.
This prospective insight can assist families in planning for future care needs while simultaneously streamlining patient identification for emerging clinical trials focused on modifying disease progression.